FDA approves chewable methylphenidate
The U.S. Food and Drug Administration on December 4 approved QuilliChew ER tablets, which Pfizer officials are calling the first and only long‐acting chewable methylphenidate treatment for attention‐deficit hyperactivity disorder (ADHD) in patients ages 6 years old and above.
Source: The Brown University Child and Adolescent Psychopharmacology Update - Category: Psychiatry Tags: From the FDA Source Type: research
More News: ADHD | Children | Concerta | Food and Drug Administration (FDA) | Hyperactivity | Methylphenidate | Pfizer | Psychiatry | Ritalin